Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • A football helmet design that listens to physics

  • 'Pushback' against constant connectivity also reflected in images

  • Does shopping helps you feel better after a setback?

  • The significance of non-motor microtubule-associated protein in maintaining synaptic plasticity thorough a novel mechanism

  • Parental preference for boys damages girls? self-esteem and happiness

  • Scientists discover molecular link between psychiatric disorders and type 2 diabetes

  • Head injury patients develop brain clumps associated with Alzheimer?s disease

  • Neurobiological changes explain how mindfulness meditation improves health

  • Athlete passion linked to acceptance of performance enhancing drugs

  • Mesh-like scaffold is disordered in Alzheimer's-affected cells

  •